These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 28065679

  • 1. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
    Singh D, Ciurlia G, Piccinno A, Muraro A, Bocchi M, Scuri M.
    Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
    [Abstract] [Full Text] [Related]

  • 2. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D, Schröder-Babo W, Cohuet G, Muraro A, Bonnet-Gonod F, Petruzzelli S, Hoffmann M, Siergiejko Z, TRIDENT study investigators.
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.
    Beeh KM, Kuna P, Corradi M, Viaud I, Guasconi A, Georges G.
    Int J Chron Obstruct Pulmon Dis; 2021 May; 16():79-89. PubMed ID: 33488071
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J, Baldi S, Zhao L, Li H, Lee KH, Singh D, Papi A, Grapin F, Guasconi A, Georges G.
    Respir Res; 2021 Mar 23; 22(1):90. PubMed ID: 33757520
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler.
    Singh D, van den Berg F, Leaker B, Corradi M, Jabbal S, Collarini S, Mongelli V, Santoro L, Piccinno A, Biondaro S, Lipworth B.
    Br J Clin Pharmacol; 2019 Apr 23; 85(4):729-736. PubMed ID: 30586199
    [Abstract] [Full Text] [Related]

  • 6. Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant.
    Rony F, Cortellini M, Guasconi A, Mathews KS, Piccinno A, Poli G, Vanhoutte F, Klein J.
    Pulm Pharmacol Ther; 2024 Jun 23; 85():102299. PubMed ID: 38663512
    [Abstract] [Full Text] [Related]

  • 7. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
    Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S.
    Pulm Pharmacol Ther; 2015 Feb 23; 30():121-7. PubMed ID: 25088067
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers.
    Luo Z, Lucci G, Santoro L, Topole E, Mariotti F.
    Pulm Pharmacol Ther; 2022 Jun 23; 73-74():102129. PubMed ID: 35525480
    [Abstract] [Full Text] [Related]

  • 9. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler® Device in Healthy Subjects, Asthmatic Patients, and COPD Patients.
    Virchow JC, Poli G, Herpich C, Kietzig C, Ehlich H, Braeutigam D, Sommerer K, Häussermann S, Mariotti F.
    J Aerosol Med Pulm Drug Deliv; 2018 Oct 23; 31(5):269-280. PubMed ID: 29989511
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J.
    Lancet; 2016 Sep 03; 388(10048):963-73. PubMed ID: 27598678
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
    Kuna P, Govoni M, Lucci G, Scuri M, Acerbi D, Stelmach I.
    Br J Clin Pharmacol; 2015 Sep 03; 80(3):569-80. PubMed ID: 25808292
    [Abstract] [Full Text] [Related]

  • 16. The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD.
    Dean J, Panainte C, Khan N, Singh D.
    Respir Res; 2020 Dec 09; 21(1):323. PubMed ID: 33298062
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.